98%
921
2 minutes
20
Purpose: The dose deposited outside of the treatment field during external photon beam radiation therapy treatment, also known as out-of-field dose, is the subject of extensive study as it may be associated with a higher risk of developing a second cancer and could have deleterious effects on the immune system that compromise the efficiency of combined radio-immunotherapy treatments. Out-of-field dose estimation tools developed today in research, including Monte Carlo simulations and analytical methods, are not suited to the requirements of clinical implementation because of their lack of versatility and their cumbersome application. We propose a proof of concept based on deep learning for out-of-field dose map estimation that addresses these limitations.
Methods And Materials: For this purpose, a 3D U-Net, considering as inputs the in-field dose, as computed by the treatment planning system, and the patient's anatomy, was trained to predict out-of-field dose maps. The cohort used for learning and performance evaluation included 3151 pediatric patients from the FCCSS database, treated in 5 clinical centers, whose whole-body dose maps were previously estimated with an empirical analytical method. The test set, composed of 433 patients, was split into 5 subdata sets, each containing patients treated with devices unseen during the training phase. Root mean square deviation evaluated only on nonzero voxels located in the out-of-field areas was computed as performance metric.
Results: Root mean square deviations of 0.28 and 0.41 cGy/Gy were obtained for the training and validation data sets, respectively. Values of 0.27, 0.26, 0.28, 0.30, and 0.45 cGy/Gy were achieved for the 6 MV linear accelerator, 16 MV linear accelerator, Alcyon cobalt irradiator, Mobiletron cobalt irradiator, and betatron device test sets, respectively.
Conclusions: This proof-of-concept approach using a convolutional neural network has demonstrated unprecedented generalizability for this task, although it remains limited, and brings us closer to an implementation compatible with clinical routine.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijrobp.2024.03.007 | DOI Listing |
Phys Med
August 2025
Princess Srisavangavadhana Faculty of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand. Electronic address:
Purpose: The aim of this work was to assess secondary cancer risks after rectal cancer intensity modulated radiation therapy (IMRT) and intensity modulated proton therapy (IMPT) using a computational phantom.
Method: A computational male phantom was used to represent Thai rectal cancer patients. Ethos treatment planning system (TPS) was used to calculate the IMRT plan with 12 fields of 6 MV flattening filter free (FFF) photon beams, while matRad was employed to calculate IMPT plans with 2 (lateral and oblique), 3 and 5 fields.
Front Oncol
July 2025
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Introduction: For indolent B-cell non-Hodgkin lymphomas (iNHLs), ultra-low-dose radiation therapy (ULDRT) with 4 Gy has demonstrated durable local control (70%), although distal relapses may occur. Concurrent systemic chemotherapy with radiation therapy (RT) extends progression-free survival (PFS) but is often avoided due to toxicity. We hypothesize that the combination of adaptive ULDRT, with repeat treatment as needed, and single-agent rituximab results in excellent local and systemic control with minimal toxicity.
View Article and Find Full Text PDFClin Transl Radiat Oncol
November 2025
Department of Radiation Oncology, Justus-Liebig-University Giessen, Giessen-Marburg University Hospital, Giessen, Germany.
Introduction: We aimed to evaluate the prevalence and patterns of locoregional recurrence (LRR), outcome and prognostic factors in patients with locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, and larynx treated with intensity-modulated or volume-modulated arc therapy definitive radiotherapy (RT) with or without systemic therapy.
Methods: Of the 213 reviewed patients treated between 2016 and 2023, 177 met the inclusion criteria. LRR was defined as recurrence in the primary tumor region or regional nodes.
Med Oncol
August 2025
Department of Radiation Oncology, The People's Hospital Affiliated to Jiangsu University, 8 Dianli Road, Runzhou District, Zhenjiang City, 212002, Jiangsu Province, China.
This study assessed the efficacy and safety of HyperArc (HA) stereotactic radiotherapy (SRT) in 48 patients with lung cancer brain metastases (LCBM) while identifying prognostic factors and high-risk predictors for symptomatic cerebral radiation necrosis (sCRN). We enrolled 48 patients diagnosed with LCBM at the People's Hospital Affiliated to Jiangsu University between February 2021 and February 2025, assigning 44 to the SRT group and 4 to the WBRT-boost group. Clinical data were collected, and all patients underwent HA stereotactic radiotherapy.
View Article and Find Full Text PDFPhys Med Biol
August 2025
Radiation Protection Dosimetry and Calibration Expert Group, Belgian Nuclear Research Center (SCK CEN), Mol, Belgium.
One major advantage of proton therapy (PT) over conventional photon radiotherapy is reduced dose delivered to normal tissue. However, the complexity of the secondary radiation field composed of a mixture of particles with a wide energy range makes its characterization a challenging task.Measurements with a miniaturized Timepix detector were carried out in three positions out-of-field (7.
View Article and Find Full Text PDF